Rybrevant Faspro, the new subcutaneous version of amivantamab, was approved for patients with a specific form of lung cancer ...

A woman who has received a breakthrough gene-editing treatment on the NHS is hoping 2026 is the year she will be cured of a major blood disorder. Kavita Mehta, 36, from London, has beta thalassaemia, ...

To help protect yourself and your family from getting seriously ill, you may want to learn about additional vaccine options ...

And for patients facing extreme limitations to mobility, or who live vast distances from hospitals and clinics, mobile ...

The CLL17 trial showed noninferiority of fixed-duration regimens compared to continuous BTK inhibitor therapy, highlighting ...

Mounjaro was brought to India eight months ago by pharma company Eli Lily.It has become India’s highest-selling drug, even replacing the antibiotic Augmentin.Meant to treatment of diabetes, it has ...

Genentech, a subsidiary of the Roche Group, has received the US FDA accelerated approval for Lunsumio VELO SC formulation to ...

US FDA approves Roche’s Lunsumio VELO for subcutaneous use in relapsed or refractory follicular lymphoma: Basel Tuesday, December 23, 2025, 13:00 Hrs [IST] Roche announced that ...

The US FDA has approved mosunetuzumab-axgb (Lunsumio VELO) as a subcutaneous (SC) formulation for the treatment of adult ...

The FDA granted accelerated approval to Lunsumio VELO for adults with relapsed/refractory follicular lymphoma after two or ...

Three years after its initial FDA approval, Roche has made up for an early disadvantage with its blood cancer drug Lunsumio ...

Lunsumio VELO reduces administration time from 2-4 hours to approximately one minute –– Availability of Lunsumio VELO allows ...